Analysts forecast that Assembly Biosciences Inc (NASDAQ:ASMB) will announce sales of $3.73 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Assembly Biosciences’ earnings, with the highest sales estimate coming in at $4.23 million and the lowest estimate coming in at $3.00 million. Assembly Biosciences posted sales of $3.74 million during the same quarter last year, which would indicate a negative year over year growth rate of 0.3%. The business is expected to announce its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that Assembly Biosciences will report full-year sales of $14.61 million for the current financial year, with estimates ranging from $13.80 million to $15.43 million. For the next year, analysts anticipate that the firm will report sales of $17.14 million, with estimates ranging from $12.00 million to $27.30 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.03). The firm had revenue of $4.23 million during the quarter, compared to the consensus estimate of $3.45 million. Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%.

Several equities analysts have issued reports on the company. BidaskClub lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 2nd. Zacks Investment Research downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th. William Blair restated a “buy” rating on shares of Assembly Biosciences in a research report on Thursday, November 7th. Chardan Capital reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, September 19th. Finally, Robert W. Baird set a $74.00 price target on Assembly Biosciences and gave the stock a “buy” rating in a report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $36.75.

In other Assembly Biosciences news, EVP Richard James Colonno sold 33,061 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $25.00, for a total transaction of $826,525.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jacqueline Sybil Papkoff sold 1,460 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $21.00, for a total value of $30,660.00. Following the sale, the senior vice president now directly owns 22,915 shares of the company’s stock, valued at $481,215. The disclosure for this sale can be found here. 12.42% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Assembly Biosciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 1,773,321 shares of the biopharmaceutical company’s stock valued at $23,921,000 after purchasing an additional 33,328 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Assembly Biosciences by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock valued at $16,552,000 after purchasing an additional 146,452 shares during the period. Rock Springs Capital Management LP boosted its holdings in Assembly Biosciences by 24.4% in the second quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock valued at $7,554,000 after acquiring an additional 110,000 shares during the last quarter. State Street Corp boosted its holdings in Assembly Biosciences by 1.2% in the third quarter. State Street Corp now owns 452,406 shares of the biopharmaceutical company’s stock valued at $4,447,000 after acquiring an additional 5,529 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Assembly Biosciences by 90.0% in the second quarter. Citadel Advisors LLC now owns 450,315 shares of the biopharmaceutical company’s stock valued at $6,075,000 after acquiring an additional 213,363 shares during the last quarter. 79.56% of the stock is owned by institutional investors and hedge funds.

Shares of Assembly Biosciences stock traded down $0.62 during trading on Friday, hitting $17.91. 407,284 shares of the stock traded hands, compared to its average volume of 355,946. The firm has a market cap of $466.50 million, a P/E ratio of -4.50 and a beta of 1.60. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a 52-week low of $8.13 and a 52-week high of $25.07. The stock’s fifty day simple moving average is $19.28 and its 200 day simple moving average is $14.50.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Why are gap-down stocks important?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.